Endovascular treatment for massive haemoptysis due to pulmonary pseudoaneurysm: report of 23 cases.

PURPOSE: To evaluate the safety and effectiveness of endovascular treatment for massive haemoptysis caused by pulmonary pseudoaneurysm (PAP). METHODS: The clinical data, imaging data, and endovascular treatment protocol of 23 patients with massive haemoptysis caused by continuous PAP were retrospectively analysed. The success, complications, postoperative recurrence rate, and influence of the treatment on pulmonary artery pressure were also evaluated. RESULTS: Nineteen patients with a bronchial artery-pulmonary artery (BA-PA) and/or nonbronchial systemic artery-pulmonary artery (NBSA-PA) fistula underwent bronchial artery embolization (BAE) and/or nonbronchial systemic artery embolization (NBSAE) + pulmonary artery embolization (PAE). The pulmonary artery (PA) pressures before and after embolization were 52.11 ± 2.12 (35-69 cmH2O) and 33.58 ± 1.63 (22-44 cmH2O), respectively (P = 0.001). Four patients did not have a BA-PA and/or NBSA-PA fistula. Embolization was performed in two patients with a distal PAP of the pulmonalis lobar arteria. Bare stent-assisted microcoils embolization was performed in the other two patients with a PAP of the main pulmonary lobar arteries. The PA pressures of the four patients before and after treatment were 24.50 ± 1.32 (22-28 cmH2O) and 24.75 ± 1.70 (22-29 cmH2O), respectively (P = 0.850). The technique had a 100% success rate with no serious complications and a postoperative recurrence rate of 30%. CONCLUSION: Endovascular treatment is safe and effective for massive haemoptysis caused by PAP. BAE and/or NBSAE can effectively reduce pulmonary hypertension in patients with a BA-PA and/or NBSA-PA fistula.

[Dual-thermotherapy for parenchymal hepatic cells carcinoma].

OBJECTIVE: To study the efficacy and safety of transhepatic arterial "dual-thermotherapy" (DT) for parenchymal hepatic cells carcinoma. METHODS: Fifty patients (mean age 55.5 years, DT group) with parenchymal hepatic cells carcinoma were treated with transhepatic arterial thermochemotherapy with warmed lipiodol (80 degrees C) and warmed chemotherapeutic agents (50 degrees C). Another 50 patients (mean age 54 years) were treated with ordinary transhepatic arterial chemomembolization (TACE) with the same chemotherapeutic drugs but without warming (TACE group). RESULTS: The 1-, 2-, and 3-year survival rates were 77.6%, 53.1% and 46.1%, respectively, in TD group; and 54.4%, 24.2% and 16.1%, resectively, in TACE group; the difference was statistically significant(P<0.05). The sidejeffect of the feeling of cauterization (cases/persistence time) in DT group was statistically significant compared with TACE group (P<0.05), and the difference was not statistically significant about other side-effects. CONCLUSION: Transhepatic arterial perfusion of warmed lipiodol (80 degrees C) and chemotherapeutic agents (50 degrees C), namely, "dual-thermotherapy" is a simple, safe and effective method for treating hepatic carcinoma with less complications than ordinary TACE.